Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Interest Expense : ¥-17 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Shenzhenlubris Pharmaceuticals Co's interest expense for the three months ended in Mar. 2024 was ¥ -4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-17 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Shenzhenlubris Pharmaceuticals Co's Operating Income for the three months ended in Mar. 2024 was ¥ 224 Mil. Shenzhenlubris Pharmaceuticals Co's Interest Expense for the three months ended in Mar. 2024 was ¥ -4 Mil. Shenzhenlubris Pharmaceuticals Co's Interest Coverage for the quarter that ended in Mar. 2024 was 56.73. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shenzhenlubris Pharmaceuticals Co Interest Expense Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Interest Expense Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-16.01

-17.57

-10.53

-12.54

-17.37

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-4.31	-4.52	-5.01	-3.54	-3.95

Shenzhenlubris Pharmaceuticals Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-17 Mil.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shenzhenlubris Pharmaceuticals Co's Interest Expense for the three months ended in Mar. 2024 was ¥-4 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥224 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ¥8 Mil.

Shenzhenlubris Pharmaceuticals Co's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	224.142	/	-3.951
	=	56.73

The higher the ratio, the stronger the company's financial strength is.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines